Integrated BioPharma (INBP) 10-Q 15 May 19 2019 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Mar. 31, 2019	May 15, 2019
Document Information [Line Items]
Entity Registrant Name	INTEGRATED BIOPHARMA INC
Entity Central Index Key	0001016504
Trading Symbol	inbp
Current Fiscal Year End Date	--06-30
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Common Stock, Shares Outstanding (in shares)		29,565,943
Document Type	10-Q
Document Period End Date	Mar. 31, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q3
Amendment Flag	false

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2019	Mar. 31, 2018
Sales, net	$ 14,088	$ 10,575	$ 36,393	$ 31,145
Cost of sales	11,995	9,106	31,750	27,623
Gross profit	2,093	1,469	4,643	3,522
Selling and administrative expenses	856	809	2,513	2,453
Operating income	1,237	660	2,130	1,069
Other income (expense), net:
Interest expense	(196)	(232)	(586)	(694)
Change in fair value of derivative liabilities		54	9	121
Impairment on investment in iBio, Inc.				(251)
Other income, net	25	9	32	13
Other expense, net	(171)	(169)	(545)	(811)
Income before income taxes	1,066	491	1,585	258
Income tax expense, net	143	103	257	397
Net income (loss)	923	388	1,328	(139)
Change in fair value of derivative liability		(54)
Interest expense on Convertible debt - CD Financial, LLC		55
Accretion of Convertible debt - CD Financial, LLC		9
Diluted net income (loss)	$ 923	$ 398	$ 1,328	$ (139)
Basic net income (loss) per common share (in dollars per share)	$ 0.03	$ 0.02	$ 0.05	$ (0.01)
Diluted net income (loss) per common share (in dollars per share)	$ 0.03	$ 0.01	$ 0.05	$ (0.01)
Weighted average common shares outstanding - basic (in shares)	29,565,943	21,135,174	28,719,452	21,135,174
Add: Equivalent shares outstanding (in shares)	542,782	836,428	582,525
Shares issuable upon conversion of Convertible Debt - CD Financial, LLC (in shares)		8,230,769
Weighted average common shares outstanding - diluted (in shares)	30,108,725	30,202,371	29,301,977	21,135,174

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Mar. 31, 2019	Jun. 30, 2018
Current Assets:
Cash	$ 431	$ 228
Accounts receivable, net	4,957	3,796
Inventories	10,549	7,741
Other current assets	413	389
Total current assets	16,350	12,154
Property and equipment, net	1,802	1,651
Right-of-use assets	3,399
Deferred tax assets, net	622	671
Security deposits and other assets	48	92
Total Assets	22,221	14,568
Current Liabilities:
Advances under revolving credit facility	6,147	4,894
Accounts payable (includes $68 and $141 due to related party)	6,036	4,184
Accrued expenses and other current liabilities	1,240	1,060
Current portion of long term debt, net	1,014	773
Current portion - Subordinated convertible note, net - CD Financial, LLC		5,269
Total current liabilities	14,437	16,180
Operating lease obligations	3,407
Long term debt, net	2,988	3,624
Total liabilities	20,832	19,804
Commitments and Contingencies
Stockholders' Equity (Deficiency):
Common Stock, $0.002 par value; 50,000,000 shares authorized; 29,600,843 and 21,170,074 shares issued, respectively; 29,565,943 and 21,135,174 shares outstanding, respectively	59	42
Additional paid-in capital	50,053	44,773
Accumulated deficit	(48,624)	(49,952)
Less: Treasury stock, at cost, 34,900 shares	(99)	(99)
Total Stockholders' Equity (Deficiency)	1,389	(5,236)
Total Liabilities and Stockholders' Equity (Deficiency)	22,221	14,568
Vitamin Realty LLC [Member]
Current Assets:
Right-of-use assets	3,345
Current Liabilities:
Operating lease obligations	3,353
Unrelated Party [Member]
Current Assets:
Right-of-use assets	54
Current Liabilities:
Operating lease obligations	$ 54

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($) $ in Thousands	Mar. 31, 2019	Jun. 30, 2018
Accounts payable, due to related parties	$ 68	$ 141
Common stock, par value (in dollars per share)	$ 0.002	$ 0.002
Common stock, share authorized (in shares)	50,000,000	50,000,000
Common stock, shares issued (in shares)	29,600,843	21,170,074
Common stock, shares outstanding (in shares)	29,565,943	21,135,174
Treasury stock, shares aquired (in shares)	34,900	34,900

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' (Deficiency) Equity (Unaudited) - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Treasury Stock [Member]	Total
Balance (in shares)	21,170,074			34,900
Balance (in shares) at Jun. 30, 2017	21,170,074			34,900
Balance at Jun. 30, 2017	$ 42	$ 44,759	$ (50,631)	$ (99)	$ (5,929)
Net income			(179)		(179)
Shares issued upon exercise of employee stock options (in shares)
Shares issued upon exercise of employee stock options		4			4
Balance (in shares)	21,170,074			34,900
Balance (in shares) at Sep. 30, 2017	29,170,074			34,900
Balance at Sep. 30, 2017	$ 42	44,763	(50,810)	$ (99)	(6,104)
Balance (in shares) at Jun. 30, 2017	21,170,074			34,900
Balance at Jun. 30, 2017	$ 42	44,759	(50,631)	$ (99)	(5,929)
Net income					(139)
Balance (in shares)	21,170,074			34,900
Balance (in shares) at Mar. 31, 2018	29,170,074			34,900
Balance at Mar. 31, 2018	$ 42	44,771	(50,770)	$ (99)	(6,056)
Balance (in shares)	29,170,074			34,900
Balance (in shares) at Sep. 30, 2017	29,170,074			34,900
Balance at Sep. 30, 2017	$ 42	44,763	(50,810)	$ (99)	(6,104)
Net income			(348)		(348)
Shares issued upon exercise of employee stock options (in shares)
Shares issued upon exercise of employee stock options		5			5
Balance (in shares)	29,170,074			34,900
Balance (in shares) at Dec. 31, 2017	29,170,074			34,900
Balance at Dec. 31, 2017	$ 42	44,768	(51,158)	$ (99)	(6,447)
Balance (in shares)	29,170,074			34,900
Net income			388		388
Shares issued upon exercise of employee stock options (in shares)
Shares issued upon exercise of employee stock options		3			3
Balance (in shares)	29,170,074			34,900
Balance (in shares) at Mar. 31, 2018	29,170,074			34,900
Balance at Mar. 31, 2018	$ 42	44,771	(50,770)	$ (99)	(6,056)
Balance (in shares)	29,170,074			34,900
Balance (in shares)	21,170,074			34,900
Balance (in shares) at Jun. 30, 2018	21,170,074			34,900
Balance at Jun. 30, 2018	$ 42	44,773	(49,952)	$ (99)	(5,236)
Shares issued upon conversion of CD Financial, LLC Convertible Note, net (in shares)	8,230,769
Shares issued upon conversion of CD Financial, LLC Convertible Note, net	$ 17	5,256			5,273
Net income			159		159
Balance (in shares)	21,170,074			34,900
Balance (in shares) at Sep. 30, 2018	29,400,843			34,900
Balance at Sep. 30, 2018	$ 59	50,029	(49,793)	$ (99)	196
Balance (in shares) at Jun. 30, 2018	21,170,074			34,900
Balance at Jun. 30, 2018	$ 42	44,773	(49,952)	$ (99)	(5,236)
Net income					1,328
Balance (in shares)	21,170,074			34,900
Balance (in shares) at Mar. 31, 2019	29,600,843			34,900
Balance at Mar. 31, 2019	$ 59	50,053	(48,624)	$ (99)	1,389
Balance (in shares)	29,400,843			34,900
Balance (in shares) at Sep. 30, 2018	29,400,843			34,900
Balance at Sep. 30, 2018	$ 59	50,029	(49,793)	$ (99)	196
Net income			246		246
Shares issued upon exercise of employee stock options (in shares)	200,000
Shares issued upon exercise of employee stock options		24			24
Balance (in shares)	29,400,843			34,900
Balance (in shares) at Dec. 31, 2018	29,600,843			34,900
Balance at Dec. 31, 2018	$ 59	50,053	(49,547)	$ (99)	466
Balance (in shares)	29,600,843			34,900
Net income			923		923
Balance (in shares)	29,600,843			34,900
Balance (in shares) at Mar. 31, 2019	29,600,843			34,900
Balance at Mar. 31, 2019	$ 59	$ 50,053	$ (48,624)	$ (99)	$ 1,389
Balance (in shares)	29,600,843			34,900

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Cash flows provided by operating activities:
Net income	$ 1,328	$ (139)
Adjustments to reconcile net income (loss) to net cash from operating activities:
Depreciation and amortization	234	264
Accretion of financing instruments and other non cash interest	46	79
Stock based compensation		12
Change in deferred tax assets	49	290
Equity loss in investment in AgroSport, LLC	12
Impairment on investment in iBio, Inc.		251
Change in fair value of derivative liabilities	(9)	(121)
Gain on sale of fixed assets		(5)
Changes in operating assets and liabilities:
Accounts receivable	(1,161)	822
Inventories	(2,807)	(910)
Other current assets	(29)	24
Security deposits and other assets	(3)
Accounts payable	1,852	697
Accrued expenses and other liabilities	189	79
Net cash (used in) provided by operating activities	(299)	1,343
Cash flows from investing activities:
Purchase of property and equipment	(350)	(216)
Cash proceeds from sale of equipment		6
Cash contribution in AgroSport LLC	(8)
Net cash used in investing activities	(358)	(210)
Cash flows from financing activities:
Advances under revolving credit facility	35,574	30,123
Proceeds from sales/lease back of equipment	233	143
Proceeds from exercise of employee stock options	24
Repayments of advances under revolving credit facility	(34,322)	(30,480)
Repayments under term note payables	(475)	(814)
Repayments under capitalized lease obligations	(174)	(175)
Net cash provided by (used in) financing activities	860	(1,203)
Net increase (decrease) in cash	203	(70)
Cash at beginning of period	228	132
Cash at end of period	431	62
Supplemental disclosures of cash flow information:
Interest paid	568	596
Income taxes paid	193	130
Supplemental disclosures of non-cash flow information:
Financing on capitalized lease obligations		$ 38

Note 1 - Principles of Consolid

Note 1 - Principles of Consolidation and Basis of Presentation	9 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	Note 1. Basis of Presentation of Interim Financial Statements The accompanying condensed consolidated financial statements for the interim periods are unaudited and include the accounts of Integrated BioPharma, Inc., a Delaware corporation (together with its subsidiaries, the “Company”). The interim condensed consolidated financial statements have been prepared in conformity with Rule 8 03 X not 10 June 30, 2018 ( 10 June 30, 2018 not nine March 31, 2019 not June 30, 2019 Nature of Operations The Company is engaged primarily in manufacturing, distributing, marketing and sales of vitamins, nutritional supplements and herbal products. The Company’s customers are located primarily in the United States, Luxembourg and Canada. The Company was previously known as Integrated Health Technologies, Inc. and, prior to that, as Chem International, Inc. The Company was reincorporated in its current form in Delaware in 1995. The Company’s business segments include: (a) Contract Manufacturing operated by InB:Manhattan Drug Company, Inc. (“MDC”), which manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers and specialized health-care providers; (b) Branded Proprietary Products operated by AgroLabs, Inc. (“AgroLabs”), which distributes healthful nutritional products for sale through major mass market, grocery and drug and vitamin retailers, under the following brands: Naturally Noni, Peaceful Sleep, Green Envy, FiberCal, Wheatgrass and other products which are being introduced into the market (these are referred to as our branded proprietary nutraceutical business and/or products); and (c) Other Nutraceutical Businesses which includes the operations of (i) The Vitamin Factory (the “Vitamin Factory”), which sells private label MDC products, as well as our AgroLabs products, through the Internet, (ii) IHT Health Products, Inc. (“IHT”) a distributor of fine natural botanicals, including multi minerals produced under a license agreement, (iii) MDC Warehousing and Distribution, Inc., a service provider for warehousing and fulfilment services and (iv) Chem International, Inc. (“Chem”), a distributor of certain raw materials for DSM Nutritional Products LLC. Accounting Policies Accounting Pronouncements Recently Adopted In May 2014, 2014 09, 606. 605, be entitled in exchange for those goods or services. The new guidance also includes a cohesive set of disclosure requirements that will provide users of financial statements with comprehensive information about the nature, amount, timing, and uncertainty of revenue and cash flows arising from a reporting organization’s contracts with customers. During 2016, No. 2016 08, 2016 10 2016 12 July 1, 2018, 8 not In January 2016, No. 2016 01, 825 10 July 1, 2018, not In February 2016, No. 2016 02, 842 The standard will be effective for us beginning July 1, 2019, July 1, 2018. not Adoption of this standard resulted in the recognition of additional ROU assets and lease liabilities for operating leases and had the following impact to the reported results as of June 30, 2018 Consolidated Statement of Financial Condition As Reported New Lease Standard Adjustment As Adjusted Operating lease right-of-use assets $ - $ 69 $ 69 Operating lease right-of-use assets - Vitamin Realty, LLC - 3,668 3,668 Operating lease liabilities - 69 69 Operating lease liabilities - Vitamin Realty, LLC - 3,677 3,677 Current portion of long term debt, net 773 - 773 Long term debt, net 3,624 - 3,624 Current portion - Subordinated convertible note, net - CD Financial, LLC 5,269 - 5,269 In August, 2016, No. 2016 15, 230 July 1, 2018 not Aside from the adoption of ASU's, as described above and the Leases policy described below, there have been no 2019 10 June 30, 2018. Significant Accoun ting P olicies Sales . Other Income . Leases. Operating lease ROU assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. As most of our leases do not may We have lease agreements with lease and non-lease components, which are generally accounted for separately. For certain equipment leases, such as vehicles, we account for the lease and non-lease components as a single lease component. Earnings Per Share. The following options and potentially dilutive shares for convertible notes payable (See Note 4. not three nine March 31, 2019 2018: Three Months Ended Nine Months Ended March 31, March 31, 2019 2018 2019 2018 Anti-dilutive stock options 150,000 150,000 150,000 2,487,584 Anti-dilutive shares for convertible note payable - - - 8,230,769 Anti-dilutive shares 150,000 150,000 150,000 10,718,353 Additionally, in the nine March 31, 2019, 8,230,769 July 24, 2018 4.

Note 2 - Inventories

Note 2 - Inventories	9 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Inventory Disclosure [Text Block]	Note 2 . Inventories Inventories are stated at the lower of cost or net realizable value using the first first March 31, June 30, 2019 2018 Raw materials $ 6,881 $ 4,179 Work-in-process 2,218 2,207 Finished goods 1,450 1,355 Total $ 10,549 $ 7,741

Note 3 - Property and Equipment

Note 3 - Property and Equipment, Net	9 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	Note 3 . Property and Equipment, net Property and equipment, net consists of the following: March 31, June 30, 2019 2018 Land and building $ 1,250 $ 1,250 Leasehold improvements 1,268 1,268 Machinery and equipment 6,231 5,917 Transportation equipment 6 6 8,755 8,441 Less: Accumulated depreciation and amortization (6,953 ) (6,790 ) Total $ 1,802 $ 1,651 Depreciation and amortization expense recorded on property and equipment was $69 $57 three March 31, 2019 2018, $201 $189 nine March 31, 2019 2018, $38 nine March 31, 2019 $146 $4 $1 nine March 31, 2018. $3 $2 nine March 31, 2018.

Note 4 - Senior Credit Facility

Note 4 - Senior Credit Facility, Subordinated Convertible Note, Net - CD Financial, LLC and Other Long Term Debt	9 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Debt Disclosure [Text Block]	Note 4 . Senior Credit Facility, Subordinated Convertible Note, net - CD Financial, LLC and other Long Term Debt As of March 31, 2019 June 30, 2018, Principal Amount Interest Rate Maturity Date As of March 31, 2019 As of June 30, 2018 Revolving advances under Senior Credit Facility with PNC Bank, National Association $ 6,147 $ 4,894 5.50 % 5/15/2024 Installment Note with PNC Bank 1,267 1,672 6.00 % 5/15/2024 Installment Note with PNC Equipment Finance 32 101 4.57 % 7/29/2019 Promissory Note with CD Financial, LLC 1,714 1,714 6.00 % 5/15/2019 Promissory Note with Vitamin Realty, LLC 686 686 4.00 % 5/15/2019 Capitalized lease obligations 328 269 4.01% - 12/1/2019- 2/1/2021 Total outstanding debt 10,174 9,336 Less: Revolving Advances (6,147 ) (4,894 ) Prepaid financing costs (25 ) (45 ) Current portion of long term debt, net (1,014 ) (773 ) Long term debt, net $ 2,988 $ 3,624 Convertible Note payable - CD Financial, LLC $ - $ 5,350 6.00 % 7/24/2018 Less: Discount for embedded derivative - (66 ) Prepaid financing costs - (15 ) Convertible Note payable, net - CD Financial, LLC $ - $ 5,269 SENIOR CREDIT FACILITY On May 15, 2019, June 27, 2012, February 19, 2016, The Amended Loan Agreement provides for a total of $11,585 $8,000 $3,585 2.50%. 3.00%. As of March 31, 2019, $4,500 $1,200 March 31, 2019 June 30, 2018 2.75% 3.25% March 31, June 30, 2019 2018 Revolving Credit Facility: Base Rate Interest 5.50 % 5.00 % Eurodollar Rate 5.24063 % n/a Term Loan: Base Rate Interest 6.00 % 5.50 % Eurodollar Rate 5.74063 % n/a Upon and after the occurrence of any event of default under the Amended Loan Agreement, and during the continuation thereof, interest shall be payable at the interest rate then applicable plus 2%. May 15, 2024 ( The principal balance of the Revolving Advances is payable on the Senior Maturity Date, subject to acceleration, based upon a material adverse event clause, as defined, subjective accelerations for borrowing base reserves, as defined or upon the occurrence of any event of default under the Amended Loan Agreement or earlier termination of the Amended Loan Agreement pursuant to the terms thereof. The Term Loan shall be repaid in eighty-four 84 first eighty-three 83 $43, first June, 2019, first The Revolving Advances are subject to the terms and conditions set forth in the Amended Loan Agreement and are made in aggregate amounts at any time equal to the lesser of ( x $8.0 85%, 75%, 85% one may The Amended Loan Agreement contains customary mandatory prepayment provisions, including, without limitation the requirement to use any sales proceeds from the sale of iBio Stock to repay the Term Loan and to prepay the outstanding amount of the Term Note in an amount equal to twenty-five 25% June 30, 2016, not one hundred twenty 120 maturities thereof. The Amended Loan Agreement also contains customary representations and warranties, covenants and events of default, including, without limitation, (i) a fixed charge coverage ratio maintenance requirement and (ii) an event of default tied to any change of control as defined in the Amended Loan Agreement. As of March 31, 2019, 25% June 30, 2016. In connection with the Senior Credit Facility, PNC and CD Financial entered into the Intercreditor and Subordination Agreement (the “Intercreditor Agreement”), which was acknowledged by the Borrowers, pursuant to which, among other things, (a) the lien of CD Financial on assets of the Borrowers is subordinated to the lien of PNC on such assets during the effectiveness of the Senior Credit Facility, and (b) priorities for payment of the debt for the Company and its subsidiaries (as described in this Note 4 In addition, in connection with the Senior Credit Facility, the following loan documents were executed: (i) a Stock Pledge Agreement with PNC, pursuant to which the Company pledged to PNC the iBio Stock; (ii) a Mortgage and Security Agreement with PNC with IHT Properties; and (iii) an Environmental Indemnity Agreement with PNC. CD FINANCIAL, LLC On June 27, 2012, February 21, 2008, 9.5% $4,500 $5,350 $1,714 July 7, 2017, February 19, 2016, February 29, 2020. The CD Notes are secured by all assets of the Borrowers, including, without limitation, machinery and equipment, real estate owned by IHT Properties, and iBio Stock owned by the Company. The CD Notes bear interest at an annual rate of 6% 10%. The CD Convertible Note is convertible at the option of CD Financial into common stock of the Company at a conversion price of $0.65 Pursuant to the terms of the Amended Loan Agreement and the Intercreditor Agreement, during the effectiveness of the Senior Credit Facility, (i) the principal of the CD Convertible Note may not may may The CD SPA contains customary representations and warranties, covenants and events of default, including, without limitation, an event of default tied to any change of control as defined in the CD SPA. In connection with the CD SPA, the Borrowers entered into an Amended and Restated Security Agreement and Amended and Restated Subsidiary Guaranty. On May 15, 2019, $1,718. On July 31, 2018, 8,230,769 3 $0.65 $0.65 As of June 30, 2018, $9 March 31, 2019 July 24, 2018. OTHER LONG TERM DEBT Related Party Debt. June 27, 2012, $686 January 10, 1997, 225 6. February 29, 2020, February 19, 2016. 4% first may On May 15, 2019, $689. ITAMIN Capitalized Lease Obligations. February 1, 2019, $233, February 1, 2021. $233, $233 $10 7.28%. On February 1, 2019, March 17, 2017 $158, $7 3.86%.

Note 5 - Significant Risks and

Note 5 - Significant Risks and Uncertainties	9 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Concentration Risk Disclosure [Text Block]	Note 5. ( a ) Major Customers . three nine March 31, 2019 2018, 92% 91% two two two 72% 22% three March 31, 2019 74% 21% three March 31, 2018, 71% 24% nine March 31, 2019 72% 22% nine March 31, 2018, two 92% 87% March 31, 2019 June 30, 2018, 10% ( b ) Other Business Risks. 72% September 1, 2018 August 31, 2021.

Note 6 - Leases and Other Commi

Note 6 - Leases and Other Commitments and Contingencies	9 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	Note 6. (a) Leases. 1 8 The components of lease expense for the three March 31, 2019 Related Party - Vitamin Realty Other Leases Totals Operating Lease Costs $ 141 $ 23 $ 164 Finance Lease Costs: Amortization of right-of use assets $ - $ 22 $ 22 Interest on operating lease liabilities - 5 5 Total Finance Lease Costs $ - $ 27 $ 27 The components of lease expense for the nine March 31, 2019 Related Party - Vitamin Realty Other Leases Totals Operating Lease Costs $ 423 $ 72 $ 495 Finance Lease Costs: Amortization of right-of use assets $ - $ 55 $ 22 Interest on operating lease liabilities - 12 12 Total Finance Lease Costs $ - $ 67 $ 67 Operating Lease Liabilities Related Party Operating L e ase Liabilities . 100% January 5, 2012, second 74,898 76,161 January 31, 2026. $533, May 19, 2014, January 5, 2012, 2,700 January 31, 2019 June 1, 2024. $27 Rent expense, lease amortization costs and interest expense on these related party leases were $203 $204 three March 31, 2019 2018, $630 $619 nine March 31, 2019 2018, March 31, 2019 June 30, 2018, $761 $827, $3,353 Other Operating Lease Liabilities . May, 2023, As of March 31, 2019, Right-of-use Assets Operating Lease Obligations Remaining Cash Commitment Vitamin Realty Leases $ 3,345 $ 3,353 $ 3,810 Machinery and equipment leases 29 29 30 Office equipment leases 25 25 26 $ 3,399 $ 3,407 $ 3,866 The Company’s weighted average discount rate and remaining term on lease liabilities is approximately 3.76% 6.6 Supplemental cash flows information related to leases for the nine March 31, 2019 Related Party - Vitamin Realty Other Leases Totals Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 424 $ 72 $ 496 Operating cash flows from capital finance lease obligations - 12 12 Financing cash flows from capital lease obligations - 174 174 The Company entered into a sales/lease back commitment in the nine March 31, 2019 $233, 4 Maturities of operating lease liabilities as of March 31, 2019 Year ending June 30, Operating Lease Commitment Related Party Operating Lease Commitment Capitalized Lease Obligations Total 2019, remaining $ 12 $ 142 $ 65 $ 219 2020 39 565 206 810 2021 22 565 77 664 2022 9 565 - 574 2023 - 565 - 565 2024 - 563 - 563 Thereafter - 845 - 845 Total minimum lease payments 82 3,810 348 4,240 Imputed interest (3 ) (457) (20 ) (480 ) Total $ 79 $ 3,353 $ 328 $ 3,760 Total $249 $245 $756 $741 three nine March 31, 2019 2018, ( b ) Legal Proceedings. The Company is subject, from time to time, to claims by third

Note 7 - Related Party Transact

Note 7 - Related Party Transactions	9 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	Note 7. See Note 4. See Note 6

Note 8 - Segment Information an

Note 8 - Segment Information and Dissaggregated Revenue	9 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	Note 8. and Disaggregated Revenue The basis for presenting segment results generally is consistent with overall Company reporting. The Company reports information about its operating segments in accordance with GAAP which establishes standards for reporting information about a company’s operating segments. The Company has divided its operations into three three March 31, 2019 2018 $1,878 $891, nine March 31, 2019 2018 $4,391 $3,797, Financial information relating to the three March 31, 2019 2018 Sales, Net Segment U.S. International Gross Capital Customers Customers Total Profit (Loss) Depreciation Expenditures Contract Manufacturing 2019 $ 11,913 $ 1,875 $ 13,788 $ 1,995 $ 68 $ 63 2018 9,333 879 10,212 1,363 55 42 Branded Proprietary Products 2019 14 3 17 7 - - 2018 - 9 9 (2 ) 1 - Other Nutraceutical Businesses 2019 283 - 283 92 1 - 2018 351 3 354 108 1 - Total Company 2019 12,210 1,878 14,088 2,093 69 63 2018 9,684 891 10,575 1,469 57 42 Financial information relating to the nine March 31, 2019 2018 Sales, Net Segment U.S. International Gross Capital Customers Customers Total Profit Depreciation Expenditures Contract Manufacturing 2019 $ 31,066 $ 4,330 $ 35,396 $ 4,323 $ 199 $ 350 2018 26,314 3,661 29,975 3,094 184 244 Branded Proprietary Products 2019 133 22 155 49 - - 2018 181 30 211 95 3 13 Other Nutraceutical Businesses 2019 803 39 842 271 2 - 2018 853 106 959 333 2 1 Total Company 2019 32,002 4,391 36,393 4,643 201 350 2018 27,348 3,797 31,145 3,522 189 258 Total Assets as of March 31, June 30, 2019 2018 Contract Manufacturing $ 19,756 $ 12,200 Branded Proprietary Products 585 543 Other Nutraceutical Businesses 1,880 1,825 Total Company $ 22,221 $ 14,568

Significant Accounting Policies

Significant Accounting Policies (Policies)	9 Months Ended
	Mar. 31, 2019
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation of Interim Financial Statements The accompanying condensed consolidated financial statements for the interim periods are unaudited and include the accounts of Integrated BioPharma, Inc., a Delaware corporation (together with its subsidiaries, the “Company”). The interim condensed consolidated financial statements have been prepared in conformity with Rule 8 03 X not 10 June 30, 2018 ( 10 June 30, 2018 not nine March 31, 2019 not June 30, 2019 Nature of Operations The Company is engaged primarily in manufacturing, distributing, marketing and sales of vitamins, nutritional supplements and herbal products. The Company’s customers are located primarily in the United States, Luxembourg and Canada. The Company was previously known as Integrated Health Technologies, Inc. and, prior to that, as Chem International, Inc. The Company was reincorporated in its current form in Delaware in 1995. The Company’s business segments include: (a) Contract Manufacturing operated by InB:Manhattan Drug Company, Inc. (“MDC”), which manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers and specialized health-care providers; (b) Branded Proprietary Products operated by AgroLabs, Inc. (“AgroLabs”), which distributes healthful nutritional products for sale through major mass market, grocery and drug and vitamin retailers, under the following brands: Naturally Noni, Peaceful Sleep, Green Envy, FiberCal, Wheatgrass and other products which are being introduced into the market (these are referred to as our branded proprietary nutraceutical business and/or products); and (c) Other Nutraceutical Businesses which includes the operations of (i) The Vitamin Factory (the “Vitamin Factory”), which sells private label MDC products, as well as our AgroLabs products, through the Internet, (ii) IHT Health Products, Inc. (“IHT”) a distributor of fine natural botanicals, including multi minerals produced under a license agreement, (iii) MDC Warehousing and Distribution, Inc., a service provider for warehousing and fulfilment services and (iv) Chem International, Inc. (“Chem”), a distributor of certain raw materials for DSM Nutritional Products LLC.
New Accounting Pronouncements, Policy [Policy Text Block]	Accounting Policies Accounting Pronouncements Recently Adopted In May 2014, 2014 09, 606. 605, be entitled in exchange for those goods or services. The new guidance also includes a cohesive set of disclosure requirements that will provide users of financial statements with comprehensive information about the nature, amount, timing, and uncertainty of revenue and cash flows arising from a reporting organization’s contracts with customers. During 2016, No. 2016 08, 2016 10 2016 12 July 1, 2018, 8 not In January 2016, No. 2016 01, 825 10 July 1, 2018, not In February 2016, No. 2016 02, 842 The standard will be effective for us beginning July 1, 2019, July 1, 2018. not Adoption of this standard resulted in the recognition of additional ROU assets and lease liabilities for operating leases and had the following impact to the reported results as of June 30, 2018 Consolidated Statement of Financial Condition As Reported New Lease Standard Adjustment As Adjusted Operating lease right-of-use assets $ - $ 69 $ 69 Operating lease right-of-use assets - Vitamin Realty, LLC - 3,668 3,668 Operating lease liabilities - 69 69 Operating lease liabilities - Vitamin Realty, LLC - 3,677 3,677 Current portion of long term debt, net 773 - 773 Long term debt, net 3,624 - 3,624 Current portion - Subordinated convertible note, net - CD Financial, LLC 5,269 - 5,269 In August, 2016, No. 2016 15, 230 July 1, 2018 not Aside from the adoption of ASU's, as described above and the Leases policy described below, there have been no 2019 10 June 30, 2018.
Revenue from Contract with Customer [Policy Text Block]	Sales .
Other Income [Policy Text Block]	Other Income .
Lessee, Leases [Policy Text Block]	Leases. Operating lease ROU assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. As most of our leases do not may We have lease agreements with lease and non-lease components, which are generally accounted for separately. For certain equipment leases, such as vehicles, we account for the lease and non-lease components as a single lease component.
Earnings Per Share, Policy [Policy Text Block]	Earnings Per Share. The following options and potentially dilutive shares for convertible notes payable (See Note 4. not three nine March 31, 2019 2018: Three Months Ended Nine Months Ended March 31, March 31, 2019 2018 2019 2018 Anti-dilutive stock options 150,000 150,000 150,000 2,487,584 Anti-dilutive shares for convertible note payable - - - 8,230,769 Anti-dilutive shares 150,000 150,000 150,000 10,718,353 Additionally, in the nine March 31, 2019, 8,230,769 July 24, 2018 4.

Note 1 - Principles of Consol_2

Note 1 - Principles of Consolidation and Basis of Presentation (Tables)	9 Months Ended
	Mar. 31, 2019
Notes Tables
Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block]	Consolidated Statement of Financial Condition As Reported New Lease Standard Adjustment As Adjusted Operating lease right-of-use assets $ - $ 69 $ 69 Operating lease right-of-use assets - Vitamin Realty, LLC - 3,668 3,668 Operating lease liabilities - 69 69 Operating lease liabilities - Vitamin Realty, LLC - 3,677 3,677 Current portion of long term debt, net 773 - 773 Long term debt, net 3,624 - 3,624 Current portion - Subordinated convertible note, net - CD Financial, LLC 5,269 - 5,269
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Three Months Ended Nine Months Ended March 31, March 31, 2019 2018 2019 2018 Anti-dilutive stock options 150,000 150,000 150,000 2,487,584 Anti-dilutive shares for convertible note payable - - - 8,230,769 Anti-dilutive shares 150,000 150,000 150,000 10,718,353

Note 2 - Inventories (Tables)

Note 2 - Inventories (Tables)	9 Months Ended
	Mar. 31, 2019
Notes Tables
Schedule of Inventory, Current [Table Text Block]	March 31, June 30, 2019 2018 Raw materials $ 6,881 $ 4,179 Work-in-process 2,218 2,207 Finished goods 1,450 1,355 Total $ 10,549 $ 7,741

Note 3 - Property and Equipme_2

Note 3 - Property and Equipment, Net (Tables)	9 Months Ended
	Mar. 31, 2019
Notes Tables
Property, Plant and Equipment [Table Text Block]	March 31, June 30, 2019 2018 Land and building $ 1,250 $ 1,250 Leasehold improvements 1,268 1,268 Machinery and equipment 6,231 5,917 Transportation equipment 6 6 8,755 8,441 Less: Accumulated depreciation and amortization (6,953 ) (6,790 ) Total $ 1,802 $ 1,651

Note 4 - Senior Credit Facili_2

Note 4 - Senior Credit Facility, Subordinated Convertible Note, Net - CD Financial, LLC and Other Long Term Debt (Tables)	9 Months Ended
	Mar. 31, 2019
Notes Tables
Schedule of Debt [Table Text Block]	Principal Amount Interest Rate Maturity Date As of March 31, 2019 As of June 30, 2018 Revolving advances under Senior Credit Facility with PNC Bank, National Association $ 6,147 $ 4,894 5.50 % 5/15/2024 Installment Note with PNC Bank 1,267 1,672 6.00 % 5/15/2024 Installment Note with PNC Equipment Finance 32 101 4.57 % 7/29/2019 Promissory Note with CD Financial, LLC 1,714 1,714 6.00 % 5/15/2019 Promissory Note with Vitamin Realty, LLC 686 686 4.00 % 5/15/2019 Capitalized lease obligations 328 269 4.01% - 12/1/2019- 2/1/2021 Total outstanding debt 10,174 9,336 Less: Revolving Advances (6,147 ) (4,894 ) Prepaid financing costs (25 ) (45 ) Current portion of long term debt, net (1,014 ) (773 ) Long term debt, net $ 2,988 $ 3,624 Convertible Note payable - CD Financial, LLC $ - $ 5,350 6.00 % 7/24/2018 Less: Discount for embedded derivative - (66 ) Prepaid financing costs - (15 ) Convertible Note payable, net - CD Financial, LLC $ - $ 5,269
Schedule of Debt Interest Rates [Table Text Block]	March 31, June 30, 2019 2018 Revolving Credit Facility: Base Rate Interest 5.50 % 5.00 % Eurodollar Rate 5.24063 % n/a Term Loan: Base Rate Interest 6.00 % 5.50 % Eurodollar Rate 5.74063 % n/a

Note 6 - Leases and Other Com_2

Note 6 - Leases and Other Commitments and Contingencies (Tables)	9 Months Ended
	Mar. 31, 2019
Notes Tables
Lease, Cost [Table Text Block]	Related Party - Vitamin Realty Other Leases Totals Operating Lease Costs $ 141 $ 23 $ 164 Finance Lease Costs: Amortization of right-of use assets $ - $ 22 $ 22 Interest on operating lease liabilities - 5 5 Total Finance Lease Costs $ - $ 27 $ 27 Related Party - Vitamin Realty Other Leases Totals Operating Lease Costs $ 423 $ 72 $ 495 Finance Lease Costs: Amortization of right-of use assets $ - $ 55 $ 22 Interest on operating lease liabilities - 12 12 Total Finance Lease Costs $ - $ 67 $ 67
Leases and Remaining Commitments [Table Text Block]	Right-of-use Assets Operating Lease Obligations Remaining Cash Commitment Vitamin Realty Leases $ 3,345 $ 3,353 $ 3,810 Machinery and equipment leases 29 29 30 Office equipment leases 25 25 26 $ 3,399 $ 3,407 $ 3,866
Supplemental Cash Flow Information, Leases [Table Text Block]	Related Party - Vitamin Realty Other Leases Totals Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 424 $ 72 $ 496 Operating cash flows from capital finance lease obligations - 12 12 Financing cash flows from capital lease obligations - 174 174
Lessee, Operating Lease and Finance Lease, Liability, Maturity [Table Text Block]	Year ending June 30, Operating Lease Commitment Related Party Operating Lease Commitment Capitalized Lease Obligations Total 2019, remaining $ 12 $ 142 $ 65 $ 219 2020 39 565 206 810 2021 22 565 77 664 2022 9 565 - 574 2023 - 565 - 565 2024 - 563 - 563 Thereafter - 845 - 845 Total minimum lease payments 82 3,810 348 4,240 Imputed interest (3 ) (457) (20 ) (480 ) Total $ 79 $ 3,353 $ 328 $ 3,760

Note 8 - Segment Information _2

Note 8 - Segment Information and Dissaggregated Revenue (Tables)	9 Months Ended
	Mar. 31, 2019
Notes Tables
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Sales, Net Segment U.S. International Gross Capital Customers Customers Total Profit (Loss) Depreciation Expenditures Contract Manufacturing 2019 $ 11,913 $ 1,875 $ 13,788 $ 1,995 $ 68 $ 63 2018 9,333 879 10,212 1,363 55 42 Branded Proprietary Products 2019 14 3 17 7 - - 2018 - 9 9 (2 ) 1 - Other Nutraceutical Businesses 2019 283 - 283 92 1 - 2018 351 3 354 108 1 - Total Company 2019 12,210 1,878 14,088 2,093 69 63 2018 9,684 891 10,575 1,469 57 42 Sales, Net Segment U.S. International Gross Capital Customers Customers Total Profit Depreciation Expenditures Contract Manufacturing 2019 $ 31,066 $ 4,330 $ 35,396 $ 4,323 $ 199 $ 350 2018 26,314 3,661 29,975 3,094 184 244 Branded Proprietary Products 2019 133 22 155 49 - - 2018 181 30 211 95 3 13 Other Nutraceutical Businesses 2019 803 39 842 271 2 - 2018 853 106 959 333 2 1 Total Company 2019 32,002 4,391 36,393 4,643 201 350 2018 27,348 3,797 31,145 3,522 189 258
Reconciliation of Assets from Segment to Consolidated [Table Text Block]	Total Assets as of March 31, June 30, 2019 2018 Contract Manufacturing $ 19,756 $ 12,200 Branded Proprietary Products 585 543 Other Nutraceutical Businesses 1,880 1,825 Total Company $ 22,221 $ 14,568

Note 1 - Principles of Consol_3

Note 1 - Principles of Consolidation and Basis of Presentation (Details Textual)	9 Months Ended
	Mar. 31, 2019shares
Common Shares Included in Calculation of Diluted EPS Attributable to Conversion of Debt Securities	8,230,769

Note 1 - Principles of Consol_4

Note 1 - Principles of Consolidation of Basis of Presentation - Adjustment to Financial Statement From Adoption of ASU 2016-02 (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Jul. 01, 2018	Jun. 30, 2018
Operating lease right-of-use assets	$ 3,399
Operating lease liabilities	3,407
Current portion of long term debt, net	1,014	$ 773	$ 773
Long-term Debt, Total	10,174	3,624	9,336
Current portion - Subordinated convertible note, net - CD Financial, LLC		5,269	5,269
Vitamin Realty LLC [Member]
Operating lease right-of-use assets	3,345	3,668
Operating lease liabilities	3,353	3,677
Unrelated Party [Member]
Operating lease right-of-use assets	54	69
Operating lease liabilities	$ 54	69
Accounting Standards Update 2016-02 [Member]
Current portion of long term debt, net			773
Long-term Debt, Total			3,624
Current portion - Subordinated convertible note, net - CD Financial, LLC			5,269
Accounting Standards Update 2016-02 [Member] | Vitamin Realty LLC [Member]
Operating lease right-of-use assets		3,668
Operating lease liabilities		3,677
Accounting Standards Update 2016-02 [Member] | Unrelated Party [Member]
Operating lease right-of-use assets		69
Operating lease liabilities		$ 69

Note 1 - Principles of Consol_5

Note 1 - Principles of Consolidation and Basis of Presentation - Antidilutive Securities Excluded From Weighted Average Diluted Common Shares Outstanding (Details) - shares	3 Months Ended		9 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2019	Mar. 31, 2018
Anti-dilutive securities (in shares)	150,000	150,000	150,000	10,718,353
Share-based Payment Arrangement, Option [Member]
Anti-dilutive securities (in shares)	150,000	150,000	150,000	2,487,584
Convertible Debt Securities [Member]
Anti-dilutive securities (in shares)				8,230,769

Note 2 - Inventories - Inventor

Note 2 - Inventories - Inventories (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Jun. 30, 2018
Raw materials	$ 6,881	$ 4,179
Work-in-process	2,218	2,207
Finished goods	1,450	1,355
Total	$ 10,549	$ 7,741

Note 3 - Property and Equipme_3

Note 3 - Property and Equipment, Net (Details Textual) - USD ($) $ in Thousands	3 Months Ended			9 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2017	Mar. 31, 2019	Mar. 31, 2018	Jun. 30, 2018
Depreciation, Total	$ 69	$ 57	$ 57	$ 201	$ 189
Property, Plant and Equipment, Disposals				38	146
Property, Plant and Equipment, Net, Ending Balance	$ 1,802			1,802		$ 1,651
Gain (Loss) on Disposition of Property Plant Equipment, Total					5
Transportation Equipment [Member]
Property, Plant and Equipment, Disposals					4
Property, Plant and Equipment, Net, Ending Balance		$ 1			1
Gain (Loss) on Disposition of Property Plant Equipment, Total					3
Machinery and Equipment [Member]
Gain (Loss) on Disposition of Property Plant Equipment, Total					$ 2

Note 3 - Property and Equipme_4

Note 3 - Property and Equipment, Net - Property and Equipment, Net (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Jun. 30, 2018	Mar. 31, 2018
Property and equipment, gross	$ 8,755	$ 8,441
Less: Accumulated depreciation and amortization	(6,953)	(6,790)
Total	1,802	1,651
Land and Building [Member]
Property and equipment, gross	1,250	1,250
Leasehold Improvements [Member]
Property and equipment, gross	1,268	1,268
Machinery and Equipment [Member]
Property and equipment, gross	6,231	5,917
Transportation Equipment [Member]
Property and equipment, gross	$ 6	$ 6
Total			$ 1

Note 4 - Senior Credit Facili_3

Note 4 - Senior Credit Facility, Subordinated Convertible Note, Net - CD Financial, LLC and Other Long Term Debt (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	May 01, 2019	Feb. 01, 2019	Jul. 31, 2018	Mar. 17, 2017	Mar. 31, 2019	Mar. 31, 2019	Mar. 31, 2018	Jun. 30, 2018	Dec. 31, 2018	Jul. 01, 2018	Feb. 19, 2016	Jun. 27, 2012	Feb. 21, 2008
Long-term Debt, Total					$ 10,174	$ 10,174		$ 9,336		$ 3,624
Capital Lease Obligations, Total					$ 328	328		$ 269
Sale Leaseback Transaction, Net Proceeds, Financing Activities, Total						233	$ 143
CD Financial LLC [Member]
Debt Instrument, Convertible, Conversion Price			$ 0.65
Stock Issued During Period, Shares, Conversion of Convertible Securities			8,230,769
First American Equipment Finance [Member]
Capital Lease Obligations, Total		$ 233		$ 158
Sale Leaseback Transaction, Net Proceeds, Financing Activities, Total		233
Sale Leaseback Transaction, Monthly Rental Payments		$ 10		$ 7
Sale Leaseback Transaction, Imputed Interest Rate		7.28%		3.86%
CD Financial LLC [Member]
Debt Instrument, Face Amount													$ 4,500
Debt Instrument, Interest Rate, Stated Percentage												6.00%	9.50%
Convertible Notes Payable, Total												$ 5,350
Debt Instrument, Convertible, Conversion Price												$ 0.65
Embedded Derivative, Fair Value of Embedded Derivative Liability									$ 9
CD Financial LLC [Member] | Default Rate [Member]
Debt Instrument, Interest Rate, Stated Percentage												10.00%
Vitamin Realty LLC [Member]
Debt Instrument, Face Amount												$ 686
Amended Loan Agreement [Member] | Term Loan [Member] | Base Rate [Member]
Debt Instrument, Basis Spread on Variable Rate					3.25%			3.25%
Long-term Debt, Total					$ 1,200	1,200
Amended Loan Agreement [Member] | Subsequent Event [Member]
Debt Instrument, Debt Default, Interest Rate Basic Spread	2.00%
Amended Loan Agreement [Member] | Subsequent Event [Member] | Term Loan [Member]
Debt Instrument, Face Amount	$ 3,585
Number of Consecutive Monthly Installments	84
Number of Consecutive Monthly Installments, Fixed Amount	83
Debt Instrument, Periodic Payment, Total	$ 43
Line of Credit Facility Covenant Prepayment Provisions Percentage of Excess Cash flow	25.00%
Amended Loan Agreement [Member] | Subsequent Event [Member] | Term Loan [Member] | Eurodollar [Member]
Debt Instrument, Basis Spread on Variable Rate	3.00%
Amended Loan Agreement [Member] | Subsequent Event [Member] | Term Loan [Member] | Base Rate [Member]
Debt Instrument, Basis Spread on Variable Rate	3.00%
Promissory Note [Member] | CD Financial LLC [Member]
Debt Instrument, Face Amount												$ 1,714
E. Gerald Kay [Member] | Vitamin Realty LLC [Member]
Debt Instrument, Interest Rate, Stated Percentage											4.00%
Revolving Credit Facility [Member] | Amended Loan Agreement [Member] | Eurodollar [Member]
Long-term Line of Credit, Total					$ 4,500	$ 4,500
Revolving Credit Facility [Member] | Amended Loan Agreement [Member] | Base Rate [Member]
Debt Instrument, Basis Spread on Variable Rate					2.75%			2.75%
Revolving Credit Facility [Member] | Amended Loan Agreement [Member] | Subsequent Event [Member]
Line of Credit Facility, Maximum Borrowing Capacity	$ 8,000
Line of Credit Facility Covenant Maximum Aggregate Revolving Advance	$ 8,000
Line of Credit Facility Covenant Aggregate Revolving Advance Receivables Advance Rate	85.00%
Line of Credit Facility Covenant Aggregate Revolving Advance Inventory Advance Rate	75.00%
Line of Credit Facility, Covenan,t Aggregate Revolving Advance, Appraised Liquidation Value, Inventory Advance Rate	85.00%
Revolving Credit Facility [Member] | Amended Loan Agreement [Member] | Subsequent Event [Member] | Eurodollar [Member]
Debt Instrument, Basis Spread on Variable Rate	2.50%
Revolving Credit Facility [Member] | Amended Loan Agreement [Member] | Subsequent Event [Member] | Base Rate [Member]
Debt Instrument, Basis Spread on Variable Rate	2.50%

Note 4 - Senior Credit Facili_4

Note 4 - Senior Credit Facility, Subordinated Convertible Note, Net - CD Financial, LLC and Other Long Term Debt - Debt Outstanding (Details) - USD ($) $ in Thousands	9 Months Ended
	Mar. 31, 2019	Jul. 01, 2018	Jun. 30, 2018
Capitalized lease obligations	$ 328		$ 269
Total outstanding debt	10,174	$ 3,624	9,336
Prepaid financing costs	(25)		(45)
Current portion of long term debt, net	(1,014)	$ (773)	(773)
Long term debt, net	$ 2,988		3,624
Minimum [Member]
Capitalized lease obligations, interest rate	4.01%
Capitalized lease obligations, maturity start date	Dec. 1, 2019
Maximum [Member]
Capitalized lease obligations, interest rate	9.38%
Capitalized lease obligations, maturity end date	Feb. 1, 2021
Revolving Advances [Member]
Notes Payable	$ 6,147		4,894
Interest Rate	5.50%
Maturity Date	May 15, 2024
Less: Revolving Advances	$ (6,147)		(4,894)
Installment Note with PNC Bank [Member]
Notes Payable	$ 1,267		1,672
Interest Rate	6.00%
Maturity Date	May 15, 2024
PNC Equipment Finance LLC [Member]
Notes Payable	$ 32		101
Interest Rate	4.57%
Maturity Date	Jul. 29, 2019
CD Financial LLC [Member]
Notes Payable	$ 1,714		1,714
Interest Rate	6.00%
Maturity Date	May 15, 2019
Vitamin Realty LLC [Member]
Notes Payable	$ 686		686
Interest Rate	4.00%
Maturity Date	May 15, 2019
Convertible Debt [Member]
Notes Payable			5,350
Interest Rate	6.00%
Maturity Date	Jul. 24, 2018
Prepaid financing costs			(15)
Less: Discount for embedded derivative			(66)
Convertible Note payable, net - CD Financial, LLC			$ 5,269

Note 4 - Senior Credit Facili_5

Note 4 - Senior Credit Facility, Subordinated Convertible Note, Net - CD Financial, LLC and Other Long Term Debt - Interest Rates (Details)	Mar. 31, 2019	Jun. 30, 2018
Revolving Credit Facility [Member] | Base Rate [Member]
Base Rate Interest	5.50%	5.00%
Revolving Credit Facility [Member] | Eurodollar [Member]
Base Rate Interest	5.24063%
Term Loan [Member] | Base Rate [Member]
Base Rate Interest	6.00%	5.50%
Term Loan [Member] | Eurodollar [Member]
Base Rate Interest	5.74063%

Note 5 - Significant Risks an_2

Note 5 - Significant Risks and Uncertainties (Details Textual)	3 Months Ended		9 Months Ended		12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2019	Mar. 31, 2018	Jun. 30, 2018
Revenue Benchmark [Member] | Customer Concentration Risk [Member]
Number of Major Customers	2	2	2	2
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Contract Manufacturing [Member]
Number of Major Customers	2	2
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Two Customers [Member]
Concentration Risk, Percentage	92.00%	91.00%	92.00%	91.00%
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Major Customer 1 [Member]
Concentration Risk, Percentage	72.00%	74.00%
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Major Customer 1 [Member] | Contract Manufacturing [Member]
Concentration Risk, Percentage			71.00%	72.00%
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Major Customer 2 [Member]
Concentration Risk, Percentage	22.00%	21.00%
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Major Customer 2 [Member] | Contract Manufacturing [Member]
Concentration Risk, Percentage			24.00%	22.00%
Accounts Receivable [Member] | Customer Concentration Risk [Member]
Number of Major Customers			2		2
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Major Customer 1 [Member]
Concentration Risk, Percentage			92.00%
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Major Customer 2 [Member]
Concentration Risk, Percentage					87.00%
Number of Employees, Geographic Area [Member] | Unionized Employees Concentration Risk [Member]
Concentration Risk, Percentage			72.00%

Note 6 - Leases and Other Com_3

Note 6 - Leases and Other Commitments and Contingencies (Details Textual) $ in Thousands	May 19, 2014USD ($)ft²	Jan. 05, 2012USD ($)ft²	Mar. 31, 2019USD ($)	Mar. 31, 2018USD ($)	Mar. 31, 2019USD ($)	Mar. 31, 2018USD ($)	Dec. 31, 2018	Jun. 30, 2018USD ($)
Unrelated Party [Member]
Operating Lease, Expense			$ 249	$ 756	$ 245	$ 741
Operating Lease, Liability, Total			$ 79		$ 79
Lessee, Operating Lease, Discount Rate							3.76%
Operating Lease, Weighted Average Remaining Lease Term			6 years 219 days		6 years 219 days
First American Equipment Finance [Member]
Sale Leaseback Transaction, Net Book Value, Total			$ 233		$ 233
Manhattan Drug Company [Member]
Payments for Rent		$ 533
AgroLabs [Member]
Area of Real Estate Property | ft²	2,700
Payments for Rent	$ 27
Chairman, Chief Executive Office and Major Stockholder [Member]
Percent of Ownership for Warehouse and Office Facilities Leased					100.00%
Vitamin Realty LLC [Member]
Operating Lease, Expense			203	$ 204	$ 630	$ 619
Due to Related Parties, Total			761		761			$ 827
Operating Lease, Liability, Total			$ 3,353		$ 3,353
Minimum [Member]
Lessee, Lease, Term of Contract					1 year
Minimum [Member] | Manhattan Drug Company [Member]
Area of Real Estate Property | ft²		74,898
Maximum [Member]
Lessee, Lease, Term of Contract					8 years
Maximum [Member] | Manhattan Drug Company [Member]
Area of Real Estate Property | ft²		76,161

Note 6 - Leases and Other Com_4

Note 6 - Leases and Other Commitments and Contingencies - Lease Expense (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Mar. 31, 2019	Mar. 31, 2019
Operating Lease Costs	$ 164	$ 495
Amortization of right-of use assets	22	22
Interest on operating lease liabilities	5	12
Total Finance Lease Costs	27	67
Unrelated Party [Member]
Operating Lease Costs	23	72
Amortization of right-of use assets	22	55
Interest on operating lease liabilities	5	12
Total Finance Lease Costs	27	67
Vitamin Realty LLC [Member]
Operating Lease Costs	141	423
Amortization of right-of use assets
Interest on operating lease liabilities
Total Finance Lease Costs

Note 6 - Leases and Other Com_5

Note 6 - Leases and Other Commitments and Contingencies - Leases and Commitments (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Jul. 01, 2018	Jun. 30, 2018
Right-of-use assets	$ 3,399
Operating lease obligations	3,407
Remaining cash commitment	3,866
Machinery and Equipment Leases [Member]
Right-of-use assets	29
Operating lease obligations	29
Remaining cash commitment	30
Office Equipment Leases [Member]
Right-of-use assets	25
Operating lease obligations	25
Remaining cash commitment	26
Vitamin Realty LLC [Member]
Right-of-use assets	3,345	$ 3,668
Operating lease obligations	3,353	$ 3,677
Remaining cash commitment	$ 3,810

Note 6 - Leases and Other Com_6

Note 6 - Leases and Other Commitments and Contingencies - Supplemental Cash Flow Information (Details) $ in Thousands	9 Months Ended
	Mar. 31, 2019USD ($)
Operating cash flows from operating leases	$ 496
Operating cash flows from capital finance lease obligations	12
Financing cash flows from capital lease obligations	174
Unrelated Party [Member]
Operating cash flows from operating leases	72
Operating cash flows from capital finance lease obligations	12
Financing cash flows from capital lease obligations	174
Vitamin Realty LLC [Member]
Operating cash flows from operating leases	424
Operating cash flows from capital finance lease obligations
Financing cash flows from capital lease obligations

Note 6 - Leases and Other Com_7

Note 6 - Leases and Other Commitments and Contingencies - Minimum Rental Commitment for Long-term Non-cancelable Leases (Details) $ in Thousands	Mar. 31, 2019USD ($)
2019, remaining, Capital Lease Obligation	$ 65
2019, remaining, Total	219
2020, Capital Lease Obligation	206
2020, Total	810
2021, Capital Lease Obligation	77
2021, Total	664
2022, Capital Lease Obligation
2022, Total	574
2023, Capital Lease Obligation
2023, Total	565
2024, Capital Lease Obligation
2024, Total	563
Thereafter, Capital Lease Obligation
Thereafter, Total	845
Total minimum lease payments, Capital Lease Obligation	348
Total minimum lease payments, Total	4,240
Imputed interest, Capital Lease Obligation	(20)
Imputed interest, Total	(480)
Total, Capital Lease Obligation	328
Total	3,760
Vitamin Realty LLC [Member]
2019, remaining, Operating Lease	142
2020, Operating Lease	565
2021, Operating Lease	565
2022, Operating Lease	565
2023, Operating Lease	565
2024, Operating Lease	563
Thereafter, Operating Lease	845
Total minimum lease payments, Operating Lease	3,810
Imputed interest, Operating Lease	(457)
Total, Operating Lease	3,353
Unrelated Party [Member]
2019, remaining, Operating Lease	12
2020, Operating Lease	39
2021, Operating Lease	22
2022, Operating Lease	9
2023, Operating Lease
2024, Operating Lease
Thereafter, Operating Lease
Total minimum lease payments, Operating Lease	82
Imputed interest, Operating Lease	(3)
Total, Operating Lease	$ 79

Note 8 - Segment Information _3

Note 8 - Segment Information and Dissaggregated Revenue (Details Textual) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2019USD ($)	Mar. 31, 2018USD ($)	Mar. 31, 2019USD ($)	Mar. 31, 2018USD ($)
Number of Reportable Segments			3
Revenue from Contract with Customer, Including Assessed Tax	$ 14,088	$ 10,575	$ 36,393	$ 31,145
Europe and Canada [Member]
Revenue from Contract with Customer, Including Assessed Tax	$ 1,878	$ 891	$ 4,391	$ 3,797

Note 8 - Segment Information _4

Note 8 - Segment Information and Dissaggregated Revenue - Operations by Business Segment (Details) - USD ($) $ in Thousands	3 Months Ended			9 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2017	Mar. 31, 2019	Mar. 31, 2018
Sales, net	$ 14,088	$ 10,575		$ 36,393	$ 31,145
Gross Profit	2,093	1,469		4,643	3,522
Depreciation	69	57	$ 57	201	189
Capital Expenditures	63	42		350	258
Contract Manufacturing [Member]
Sales, net	13,788	10,212		35,396	29,975
Gross Profit	1,995	1,363		4,323	3,094
Depreciation	68	55		199	184
Capital Expenditures	63	42		350	244
Branded Proprietary Products [Member]
Sales, net	17	9		155	211
Gross Profit	7	(2)		49	95
Depreciation		1			3
Capital Expenditures					13
Other Nutraceutical Business [Member]
Sales, net	283	354		842	959
Gross Profit	92	108		271	333
Depreciation	1	1		2	2
Capital Expenditures					1
UNITED STATES
Sales, net	12,210	9,684		32,002	27,348
UNITED STATES | Contract Manufacturing [Member]
Sales, net	11,913	9,333		31,066	26,314
UNITED STATES | Branded Proprietary Products [Member]
Sales, net	14			133	181
UNITED STATES | Other Nutraceutical Business [Member]
Sales, net	283	351		803	853
Non-US [Member]
Sales, net	1,878	891		4,391	3,797
Non-US [Member] | Contract Manufacturing [Member]
Sales, net	1,875	879		4,330	3,661
Non-US [Member] | Branded Proprietary Products [Member]
Sales, net	3	9		22	30
Non-US [Member] | Other Nutraceutical Business [Member]
Sales, net		$ 3		$ 39	$ 106

Note 8 - Segment Information _5

Note 8 - Segment Information and Dissaggregated Revenue - Total Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Jun. 30, 2018
Total Assets	$ 22,221	$ 14,568
Contract Manufacturing [Member]
Total Assets	19,756	12,200
Branded Proprietary Products [Member]
Total Assets	585	543
Other Nutraceutical Business [Member]
Total Assets	$ 1,880	$ 1,825